Document is current
Any future updates will be listed below
-
Authors
Dantas, Ezequiel
Hootman, Katie C. https://orcid.org/0000-0003-0476-3454
Moyer, Jenna https://orcid.org/0000-0002-4599-2969
Tomberlin, Morgan
Curran, Katherine
Ramesh, Bhavani
Price, Hannah https://orcid.org/0009-0001-7909-1712
Kim, Jeshua https://orcid.org/0009-0002-0464-1633
McPherson, Alex C. https://orcid.org/0000-0001-8994-0880
Hurd, Maurice A.
Zhu, Yuan-Shan
Plodkowski, Andrew J. https://orcid.org/0000-0002-3772-370X
Nagase, Erica
Tsomides, Anastasia
Cuevas, Brandon M. https://orcid.org/0000-0002-8275-8258
Martin, M. Laura
Nguyen, John https://orcid.org/0009-0007-0560-6684
Bennetti, Gabrielle
Rodriguez, Gissell Botero
Chang, Kaity
Mezzancello, Marissa
Gardner, Ginger J.
Broach, Vance
Mueller, Jennifer J.
Sonoda, Yukio
Zivanovic, Oliver
Leitao, Mario M. Jr
Iasonos, Alexia
Soldan, Krysten
Carthew, Karen
Hom, Vania
Villamater, Francis N.
Chaari, Rema Rao https://orcid.org/0000-0003-2462-0004
Gorski, Kathryn https://orcid.org/0009-0005-6277-9691
Sigouros, Michael https://orcid.org/0000-0002-0328-8359
Aghajanian, Carol
Elemento, Olivier https://orcid.org/0000-0002-8061-9617
Cantley, Lewis C.
Hopkins, Benjamin D. https://orcid.org/0000-0002-7970-6430
Weigelt, Britta https://orcid.org/0000-0001-9927-1270
Ellenson, Lora H.
Hacker, Kari
Abu-Rustum, Nadeem R.
Makker, Vicky https://orcid.org/0000-0001-9793-7614
Goncalves, Marcus D. https://orcid.org/0000-0002-0784-9248
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01CA279561)
- License Information
-
More Information
Article History
Received: 21 October 2024
Accepted: 5 May 2026
First Online: 27 May 2026
Competing interests
: M.D.G. holds equity in Faeth Therapeutics and Skye Biosciences; reports consulting or advisory roles with Almac Discovery, Faeth Therapeutics, Genentech Inc., Scorpion Therapeutics, Skye Biosciences, and Third Arc Bio, Inc.; patents, royalties, and other intellectual property with Weill Cornell Medicine and Faeth Therapeutics. E.D. reports intellectual property with Weill Cornell Medicine. L.C.C. is a founder and member of the board of directors of Agios Pharmaceuticals and is a founder and receives research support from Petra Pharmaceuticals; is listed as an inventor on a patent with Weill Cornell Medicine; is a cofounder and shareholder in Faeth Therapeutics; has equity in and consults for Cell Signaling Technologies, Volastra, Larkspur and 1 Base Pharmaceuticals; and consults for Loxo-Lilly. B.D.H. is a cofounder and stockholder in Faeth Therapeutics. V.M. has institutional grants or contracts with AstraZeneca, Bristol Myers Squibb, Cullinan Oncology, DualityBio, Eisai, Faeth Therapeutics, Karyopharm Therapeutics, Merck, Takeda, and Zymeworks; receives personal meeting/travel support from AstraZeneca; and is an unpaid consultant for Clovis Oncology, Cullinan Oncology, DualityBio, Eisai, Faeth Therapeutics, Jazz Pharmaceuticals, GlaxoSmithKline, Immunocore, iTeos Therapeutics, Karyopharm Therapeutics, Lilly, Merck, Mereo BioPharma, MorphoSys, MSD, Novartis, Regeneron, Sutro Biopharma, and Zymeworks. All other authors report no conflicts of interest.
